세계의 안구건조증 치료 시장 - 산업 규모, 점유율, 동향, 기회, 예측 : 적응증별, 제품 유형별, 제형별, 유형별, 유통 채널별, 지역별 경쟁(2020-2030년)

The Global Dry Eye Syndrome Treatment Market was valued at USD 6.31 billion in 2024 and is projected to reach USD 9.15 billion by 2030, growing at a CAGR of 6.39% during the forecast period. This growth is driven by the increasing prevalence of dry eye conditions linked to autoimmune diseases such as rheumatoid arthritis, lupus, and thyroid disorders. Rising approvals of innovative drug therapies and eye drop formulations, coupled with advancements in R&D for dry eye management, are propelling market expansion. Technological progress, such as intranasal tear neurostimulation devices that promote tear production, is also fostering demand. Additionally, a growing influx of new market entrants is accelerating regulatory approvals and broadening treatment accessibility. However, limited public awareness and underdiagnosis remain significant hurdles for market penetration.

Key Market Drivers

Rising Geriatric Population and Age-Related Ocular Conditions

The expanding elderly demographic is a key driver for the global dry eye syndrome treatment market, as aging is closely linked to reduced tear production and gland function. Data from the United Nations Department of Economic and Social Affairs indicates that the global population aged 65 and over will exceed 1.6 billion by 2050. Older individuals are more susceptible to dry eye symptoms due to age-related degradation of tear film and meibomian gland health. In the United States, nearly 15% of adults over 50 report symptoms of dry eye, particularly among women. This demographic trend is creating sustained demand for targeted dry eye treatments, especially in developed regions where aging populations are most pronounced.

Key Market Challenges

Low Patient Awareness and Underdiagnosis

Despite its growing prevalence, dry eye syndrome remains significantly underdiagnosed due to limited public awareness and misconceptions about symptoms. Many individuals attribute discomfort to temporary factors and delay seeking professional care, leading to untreated cases. According to the U.S. National Eye Institute, a majority of dry eye sufferers remain undiagnosed, particularly in lower-income regions with limited access to specialized care. Additionally, inconsistent diagnostic standards and limited practitioner training contribute to misclassification and reliance on over-the-counter products. Cultural attitudes and the low prioritization of eye health in some countries further exacerbate this issue, restricting treatment adoption and hindering market growth.

Key Market Trends

Integration of Artificial Intelligence and Diagnostic Technologies

Artificial intelligence and advanced diagnostic tools are transforming how dry eye syndrome is detected and managed. AI-based imaging systems are increasingly used to assess tear stability, gland function, and ocular surface conditions with higher accuracy than manual observation. These tools are essential in streamlining diagnostics, particularly in teleophthalmology and high-volume clinical settings. Regulatory and funding support, such as the FDA's approval of AI diagnostic tools and the NIH's investments in healthcare AI, are accelerating adoption. Countries like Japan and South Korea are implementing AI within smart hospitals to enhance diagnostic efficiency. This technological integration supports early intervention, improves treatment outcomes, and lowers long-term healthcare expenditures related to untreated dry eye.

Key Market Players

• Johnson & Johnson Services, Inc.
• AbbVie Inc.
• Bausch Health Companies Inc.
• Novartis AG
• Sun Pharmaceuticals Industries Limited
• Santen Pharmaceutical Co., Ltd.
• Otsuka Pharmaceutical Co., Ltd.
• Oyster Point Pharma, Inc.
• Alcon Inc.
• GlaxoSmithKline plc

Report Scope:

In this report, the Global Dry Eye Syndrome Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dry Eye Syndrome Treatment Market, By Indication:

• Evaporative Dry Eye Syndrome
• Aqueous Deficient Dry Eye Syndrome

Dry Eye Syndrome Treatment Market, By Product Type:

• Cyclosporine
• Topical Corticosteroids
• Artificial Tears
• Punctal Plugs
• Others

Dry Eye Syndrome Treatment Market, By Dosage Form:

• Gels
• Eye Solutions
• Capsules & Tablets
• Eye Drops
• Ointments

Dry Eye Syndrome Treatment Market, By Type:

• Prescription
• Over The Counter

Dry Eye Syndrome Treatment Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Dry Eye Syndrome Treatment Market, By Region:

• North America
  • United States
  • Mexico
  • Canada
• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
• Asia-Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dry Eye Syndrome Treatment Market.

Available Customizations:

Global Dry Eye Syndrome Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

• 5.1. Ongoing Clinical Trials
• 5.2. Completed Clinical Trials
• 5.3. Terminated Clinical Trials
• 5.4. Breakdown of Pipeline, By Development Phase
• 5.5. Breakdown of Pipeline, By Status
• 5.6. Breakdown of Pipeline, By Study Type
• 5.7. Breakdown of Pipeline, By Region
• 5.8. Clinical Trials Heat Map

6. Global Dry Eye Syndrome Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Indication (Evaporative Dry Eye Syndrome, Aqueous Deficient Dry Eye Syndrome)
  • 6.2.2. By Product Type (Cyclosporine, Topical Corticosteroids, Artificial Tears, Punctal Plugs, Others)
  • 6.2.3. By Dosage Form (Gels, Eye Solutions, Capsules & Tablets, Eye Drops, Ointments)
  • 6.2.4. By Type (Prescription, Over The Counter)
  • 6.2.5. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 6.2.6. By Region
  • 6.2.7. By Company (2024)
• 6.3. Market Map
  • 6.3.1. By Indication
  • 6.3.2. By Product Type
  • 6.3.3. By Dosage Form
  • 6.3.4. By Type
  • 6.3.5. By Distribution Channel
  • 6.3.6. By Region

7. North America Dry Eye Syndrome Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Indication
  • 7.2.2. By Product Type
  • 7.2.3. By Dosage Form
  • 7.2.4. By Type
  • 7.2.5. By Distribution Channel
  • 7.2.6. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Dry Eye Syndrome Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Indication
      • 7.3.1.2.2. By Product Type
      • 7.3.1.2.3. By Dosage Form
      • 7.3.1.2.4. By Type
      • 7.3.1.2.5. By Distribution Channel
  • 7.3.2. Canada Dry Eye Syndrome Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Indication
      • 7.3.2.2.2. By Product Type
      • 7.3.2.2.3. By Dosage Form
      • 7.3.2.2.4. By Type
      • 7.3.2.2.5. By Distribution Channel
  • 7.3.3. Mexico Dry Eye Syndrome Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Indication
      • 7.3.3.2.2. By Product Type
      • 7.3.3.2.3. By Dosage Form
      • 7.3.3.2.4. By Type
      • 7.3.3.2.5. By Distribution Channel

8. Europe Dry Eye Syndrome Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Indication
  • 8.2.2. By Product Type
  • 8.2.3. By Dosage Form
  • 8.2.4. By Type
  • 8.2.5. By Distribution Channel
  • 8.2.6. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. France Dry Eye Syndrome Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Indication
      • 8.3.1.2.2. By Product Type
      • 8.3.1.2.3. By Dosage Form
      • 8.3.1.2.4. By Type
      • 8.3.1.2.5. By Distribution Channel
  • 8.3.2. Germany Dry Eye Syndrome Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Indication
      • 8.3.2.2.2. By Product Type
      • 8.3.2.2.3. By Dosage Form
      • 8.3.2.2.4. By Type
      • 8.3.2.2.5. By Distribution Channel
  • 8.3.3. United Kingdom Dry Eye Syndrome Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Indication
      • 8.3.3.2.2. By Product Type
      • 8.3.3.2.3. By Dosage Form
      • 8.3.3.2.4. By Type
      • 8.3.3.2.5. By Distribution Channel
  • 8.3.4. Italy Dry Eye Syndrome Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Indication
      • 8.3.4.2.2. By Product Type
      • 8.3.4.2.3. By Dosage Form
      • 8.3.4.2.4. By Type
      • 8.3.4.2.5. By Distribution Channel
  • 8.3.5. Spain Dry Eye Syndrome Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Indication
      • 8.3.5.2.2. By Product Type
      • 8.3.5.2.3. By Dosage Form
      • 8.3.5.2.4. By Type
      • 8.3.5.2.5. By Distribution Channel

9. Asia-Pacific Dry Eye Syndrome Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Indication
  • 9.2.2. By Product Type
  • 9.2.3. By Dosage Form
  • 9.2.4. By Type
  • 9.2.5. By Distribution Channel
  • 9.2.6. By Country
• 9.3. Asia-Pacific: Country Analysis
  • 9.3.1. China Dry Eye Syndrome Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Indication
      • 9.3.1.2.2. By Product Type
      • 9.3.1.2.3. By Dosage Form
      • 9.3.1.2.4. By Type
      • 9.3.1.2.5. By Distribution Channel
  • 9.3.2. India Dry Eye Syndrome Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Indication
      • 9.3.2.2.2. By Product Type
      • 9.3.2.2.3. By Dosage Form
      • 9.3.2.2.4. By Type
      • 9.3.2.2.5. By Distribution Channel
  • 9.3.3. Japan Dry Eye Syndrome Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Indication
      • 9.3.3.2.2. By Product Type
      • 9.3.3.2.3. By Dosage Form
      • 9.3.3.2.4. By Type
      • 9.3.3.2.5. By Distribution Channel
  • 9.3.4. South Korea Dry Eye Syndrome Treatment Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Indication
      • 9.3.4.2.2. By Product Type
      • 9.3.4.2.3. By Dosage Form
      • 9.3.4.2.4. By Type
      • 9.3.4.2.5. By Distribution Channel
  • 9.3.5. Australia Dry Eye Syndrome Treatment Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Indication
      • 9.3.5.2.2. By Product Type
      • 9.3.5.2.3. By Dosage Form
      • 9.3.5.2.4. By Type
      • 9.3.5.2.5. By Distribution Channel

10. South America Dry Eye Syndrome Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Indication
  • 10.2.2. By Product Type
  • 10.2.3. By Dosage Form
  • 10.2.4. By Type
  • 10.2.5. By Distribution Channel
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Dry Eye Syndrome Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Indication
      • 10.3.1.2.2. By Product Type
      • 10.3.1.2.3. By Dosage Form
      • 10.3.1.2.4. By Type
      • 10.3.1.2.5. By Distribution Channel
  • 10.3.2. Argentina Dry Eye Syndrome Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Indication
      • 10.3.2.2.2. By Product Type
      • 10.3.2.2.3. By Dosage Form
      • 10.3.2.2.4. By Type
      • 10.3.2.2.5. By Distribution Channel
  • 10.3.3. Colombia Dry Eye Syndrome Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Indication
      • 10.3.3.2.2. By Product Type
      • 10.3.3.2.3. By Dosage Form
      • 10.3.3.2.4. By Type
      • 10.3.3.2.5. By Distribution Channel

11. Middle East and Africa Dry Eye Syndrome Treatment Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Indication
  • 11.2.2. By Product Type
  • 11.2.3. By Dosage Form
  • 11.2.4. By Type
  • 11.2.5. By Distribution Channel
  • 11.2.6. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. South Africa Dry Eye Syndrome Treatment Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Indication
      • 11.3.1.2.2. By Product Type
      • 11.3.1.2.3. By Dosage Form
      • 11.3.1.2.4. By Type
      • 11.3.1.2.5. By Distribution Channel
  • 11.3.2. Saudi Arabia Dry Eye Syndrome Treatment Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Indication
      • 11.3.2.2.2. By Product Type
      • 11.3.2.2.3. By Dosage Form
      • 11.3.2.2.4. By Type
      • 11.3.2.2.5. By Distribution Channel
  • 11.3.3. UAE Dry Eye Syndrome Treatment Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Indication
      • 11.3.3.2.2. By Product Type
      • 11.3.3.2.3. By Dosage Form
      • 11.3.3.2.4. By Type
      • 11.3.3.2.5. By Distribution Channel

12. Market Dynamics

• 12.1. Drivers
• 12.2. Challenges

13. Market Trends & Developments

• 13.1. Recent Developments
• 13.2. Mergers & Acquisitions
• 13.3. Product Launches

14. Global Dry Eye Syndrome Treatment Market: SWOT Analysis

15. Porters Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Products/Services

16. Competitive Landscape

• 16.1. Johnson & Johnson Services, Inc.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (As Reported)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.7. SWOT Analysis
• 16.2. AbbVie Inc.
• 16.3. Bausch Health Companies Inc.
• 16.4. Novartis AG
• 16.5. Sun Pharmaceuticals Industries Limited
• 16.6. Santen Pharmaceutical Co., Ltd.
• 16.7. Otsuka Pharmaceutical Co., Ltd.
• 16.8. Oyster Point Pharma, Inc.
• 16.9. Alcon Inc.
• 16.10. GlaxoSmithKline plc

17. Strategic Recommendations

18. About Us & Disclaimer